| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:LSD1-IN-20
CAS:1239589-91-3
Purity:98.00% Package:1mg;5mg;25mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:LSD1-IN-20
CAS:1239589-91-3
Purity:98.72% Package:1mg/RMB 2350;5mg/RMB 7000;25mg/RMB 10600
|
|
| | 2,4-Quinazolinediamine, N2-[3-(dimethylamino)propyl]-6,7-dimethoxy-N4-[1-(phenylmethyl)-4-piperidinyl]- Basic information |
| | 2,4-Quinazolinediamine, N2-[3-(dimethylamino)propyl]-6,7-dimethoxy-N4-[1-(phenylmethyl)-4-piperidinyl]- Chemical Properties |
| Boiling point | 637.3±65.0 °C(Predicted) | | density | 1.190±0.06 g/cm3(Predicted) | | pka | 9.47±0.28(Predicted) |
| | 2,4-Quinazolinediamine, N2-[3-(dimethylamino)propyl]-6,7-dimethoxy-N4-[1-(phenylmethyl)-4-piperidinyl]- Usage And Synthesis |
| Uses | LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with Ki values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC50 (72 h) of 0.51 and 1.60 μM, respectively[1]. | | References | [1] Menna M, et al. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. Eur J Med Chem. 2022 Jul 5;237:114410. DOI:10.1016/j.ejmech.2022.114410 |
| | 2,4-Quinazolinediamine, N2-[3-(dimethylamino)propyl]-6,7-dimethoxy-N4-[1-(phenylmethyl)-4-piperidinyl]- Preparation Products And Raw materials |
|